Rufinamide→see antiepileptics
Rupatadine→see antihistamines, non-sedating
Ruxolitinib→seeTABLE 15p. 850 (myelosuppression)
▶Antiarrhythmics(dronedarone)are predicted to increase the
exposure toruxolitinib.oTheoretical
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to decrease the exposure
toruxolitinib. Monitor and adjust dose.oStudy
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure toruxolitinib.o
Theoretical
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure toruxolitinib. Adjust dose
and monitor side effects.oStudy
▶Aprepitantis predicted to increase the exposure toruxolitinib.
oTheoretical
▶Bosentanis predicted to decrease the exposure toruxolitinib.
Monitor and adjust dose.oTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure toruxolitinib.oTheoretical
▶Cobicistatis predicted to increase the exposure toruxolitinib.
Adjust dose and monitor side effects.oStudy
▶Ruxolitinibis predicted to increase the risk of bleeding events
when given withcoumarins.rTheoretical
▶Crizotinibis predicted to increase the exposure toruxolitinib.
oTheoretical→Also seeTABLE 15p. 850
▶Efavirenzis predicted to decrease the exposure toruxolitinib.
Monitor and adjust dose.oTheoretical
▶Enzalutamideis predicted to decrease the exposure to
ruxolitinib. Monitor and adjust dose.oStudy
▶Grapefruit juiceis predicted to increase the exposure to
ruxolitinib.rTheoretical
▶HIV-protease inhibitorsare predicted to increase the exposure
toruxolitinib. Adjust dose and monitor side effects.o
Study
▶Idelalisibis predicted to increase the exposure toruxolitinib.
Adjust dose and monitor side effects.oStudy→Also see
TABLE 15p. 850
▶Imatinibis predicted to increase the exposure toruxolitinib.
oTheoretical→Also seeTABLE 15p. 850
▶Macrolides(clarithromycin)are predicted to increase the
exposure toruxolitinib. Adjust dose and monitor side effects.
oStudy
▶Macrolides(erythromycin)are predicted to increase the
exposure toruxolitinib.oTheoretical
▶Mitotaneis predicted to decrease the exposure toruxolitinib.
Monitor and adjust dose.oStudy→Also seeTABLE 15
p. 850
▶Netupitantis predicted to increase the exposure toruxolitinib.
oTheoretical
▶Nevirapineis predicted to decrease the exposure toruxolitinib.
Monitor and adjust dose.oTheoretical
▶Nilotinibis predicted to increase the exposure toruxolitinib.
oTheoretical→Also seeTABLE 15p. 850
▶Ruxolitinibis predicted to increase the risk of bleeding events
when given withphenindione.rTheoretical
▶Rifampicinis predicted to decrease the exposure toruxolitinib.
Monitor and adjust dose.oStudy
▶St John’s Wortis predicted to decrease the exposure to
ruxolitinib. Monitor and adjust dose.oTheoretical
Sacubitril→seeTABLE 8p. 848 (hypotension)
▶Sacubitrilis predicted to increase the exposure tostatins.
rStudy
Safinamide→see monoamine-oxidase B inhibitors
Salbutamol→see beta 2 agonists
Salmeterol→see beta 2 agonists
Sapropterin→seeTABLE 8p. 848 (hypotension)
▶Methotrexateis predicted to decrease the efficacy of
sapropterin.oTheoretical
▶Phosphodiesterase type-5 inhibitorsare predicted to increase
the risk of hypotension when given withsapropterin.o
Theoretical→Also seeTABLE 8p. 848
▶Trimethoprimis predicted to decrease the efficacy of
sapropterin.oTheoretical
Saquinavir→see HIV-protease inhibitors
Sarilumab→see monoclonal antibodies
Saxagliptin→seeTABLE 14p. 850 (antidiabetic drugs)
▶Antiarrhythmics(dronedarone)are predicted to increase the
exposure tosaxagliptin.nStudy
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to moderately decrease
the exposure tosaxagliptin.oStudy
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure tosaxagliptin.n
Study
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure tosaxagliptin.o
Study
▶Aprepitantis predicted to increase the exposure tosaxagliptin.
nStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tosaxagliptin.nStudy
▶Cobicistatis predicted to increase the exposure tosaxagliptin.
oStudy
▶Crizotinibis predicted to increase the exposure tosaxagliptin.
nStudy
▶Enzalutamideis predicted to moderately decrease the
exposure tosaxagliptin.oStudy
▶Grapefruit juiceis predicted to increase the exposure to
saxagliptin.nTheoretical
▶HIV-protease inhibitorsare predicted to increase the exposure
tosaxagliptin.oStudy
▶Idelalisibis predicted to increase the exposure tosaxagliptin.
oStudy
▶Imatinibis predicted to increase the exposure tosaxagliptin.
nStudy
▶Macrolides(clarithromycin)are predicted to increase the
exposure tosaxagliptin.oStudy
▶Macrolides(erythromycin)are predicted to increase the
exposure tosaxagliptin.nStudy
▶Mitotaneis predicted to moderately decrease the exposure to
saxagliptin.oStudy
▶Netupitantis predicted to increase the exposure tosaxagliptin.
nStudy
▶Nilotinibis predicted to increase the exposure tosaxagliptin.
nStudy
▶Rifampicinis predicted to moderately decrease the exposure
tosaxagliptin.oStudy
Secukinumab→see monoclonal antibodies
Selegiline→see monoamine-oxidase B inhibitors
Selenium
▶Seleniumis predicted to decrease the absorption of
eltrombopag.Eltrombopagshould be taken 2 hours before or
4 hours afterselenium,p. 582.rTheoretical
Selexipag
▶Antiepileptics(carbamazepine, fosphenytoin, phenytoin)are
predicted to decrease the exposure to the active metabolite of
selexipag. Adjust dose.oStudy
▶Antiepileptics(valproate)are predicted to increase the exposure
toselexipag.qTheoretical
▶Antifungals, azoles(fluconazole)are predicted to increase the
exposure toselexipag.qTheoretical
▶Clopidogrelis predicted to increase the exposure toselexipag.
Adjust dose.oStudy
▶Fibrates(gemfibrozil)increase the exposure toselexipag.
Avoid.rStudy
▶Iron chelators(deferasirox)are predicted to increase the
exposure toselexipag. Adjust dose.oStudy
▶Leflunomideis predicted to increase the exposure toselexipag.
Adjust dose.oTheoretical
▶Rifampicinmoderately decreases the exposure to the active
metabolite ofselexipag. Adjust dose.oStudy
▶Teriflunomideis predicted to increase the exposure to
selexipag. Adjust dose.oTheoretical
Sertraline→see SSRIs
Sevoflurane→see volatile halogenated anaesthetics
Sildenafil→see phosphodiesterase type-5 inhibitors
Siltuximab→see monoclonal antibodiesBNFC 2018 – 2019 Rufinamide—Siltuximab 987
Interactions|Appendix 1A1